JAK2V617F leads to intrinsic changes in platelet formation and reactivity in a knock-in mouse model of essential thrombocythemia.
about
Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategiesQuantitative histological image analyses of reticulin fibers in a myelofibrotic mouseAnti-Platelet Factor 4/Heparin Antibody Formation Occurs Endogenously and at Unexpected High Frequency in Polycythemia Vera.Increased B cell activation is present in JAK2V617F-mutated, CALR-mutated and triple-negative essential thrombocythemia.Mechanisms of thrombogenesis in polycythemia veraLysyl oxidase is associated with increased thrombosis and platelet reactivity.Splanchnic vein thrombosis in myeloproliferative neoplasms: pathophysiology and molecular mechanisms of disease.Lessons and Implications from Genome-Wide Association Studies (GWAS) Findings of Blood Cell Phenotypes.A novel signalling screen demonstrates that CALR mutations activate essential MAPK signalling and facilitate megakaryocyte differentiation.Assessing the thrombotic risk of patients with essential thrombocythemia in the genomic era.Causal role for JAK2 V617F in thrombosis.Hemostatic disorders in a JAK2V617F-driven mouse model of myeloproliferative neoplasmMicroparticle phenotypes are associated with driver mutations and distinct thrombotic risks in essential thrombocythemia.Is JAK2V617F finally off the hook?The effects of JAK inhibitor therapy upon novel markers of thrombosis In myeloproliferative neoplasms.Phosphatidylserine-exposing blood and endothelial cells contribute to the hypercoagulable state in essential thrombocythemia patients.SOHO State-of-the-Art Update and Next Questions: MPN.The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review.Increased mean platelet volume and immature platelet fraction as potential predictors of thrombotic complications in BCR/ABL-negative myeloproliferative neoplasms.
P2860
Q26744113-EFA36C29-4877-4E28-A55A-99C6064910D5Q28364884-513A1B8A-2C3D-4C69-9FA6-47B593599D30Q33443580-357666C8-C485-4B36-A35B-A7D0BD41DC78Q33779135-8D804BE6-5F13-4B8E-9BCA-4C4D6A62C420Q35738656-71B6F225-D206-44F3-9DE3-97852A559ED5Q36700494-EEEF6757-6C39-401B-A184-B5E204D303D9Q37638779-4032210A-3E64-406E-BA60-64364DCA4A23Q37689829-DF146E30-D05C-43A6-ABB6-5CE6CE08FA3AQ37740931-5CC2D33C-DF85-4EF3-AC32-FA22C84C6393Q39321106-A5119D21-7DBB-41C9-A050-72FE330EA907Q41845478-236ADE0C-5EED-45BD-B0FC-BEDBF8B66930Q42189605-E3634263-C009-4975-B673-490270286745Q42384356-EDA7C545-62E8-46AD-9892-8461219A153AQ42791781-3C277AC1-300D-42E8-B43A-7A08E87C7574Q42943367-C1F94E24-0472-46FA-80F3-4DDF29DC93A1Q48248231-2B714D30-0798-467A-B97D-5AE3B3E36CD4Q49580473-C631FE5A-AC8E-4771-B1DB-C8B841DA451CQ53111428-A3BCD85A-2539-4824-88F8-1E8A76BA01BBQ54321775-F780F66C-B367-4364-83FC-EC10958E36B4
P2860
JAK2V617F leads to intrinsic changes in platelet formation and reactivity in a knock-in mouse model of essential thrombocythemia.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
JAK2V617F leads to intrinsic c ...... of essential thrombocythemia.
@en
JAK2V617F leads to intrinsic c ...... of essential thrombocythemia.
@nl
type
label
JAK2V617F leads to intrinsic c ...... of essential thrombocythemia.
@en
JAK2V617F leads to intrinsic c ...... of essential thrombocythemia.
@nl
prefLabel
JAK2V617F leads to intrinsic c ...... of essential thrombocythemia.
@en
JAK2V617F leads to intrinsic c ...... of essential thrombocythemia.
@nl
P2093
P2860
P50
P1433
P1476
JAK2V617F leads to intrinsic c ...... of essential thrombocythemia.
@en
P2093
Catherine M Hobbs
Harriet Manning
Jose A Guerrero
Lauren Brain
Louella Vasquez
P2860
P304
P356
10.1182/BLOOD-2013-06-501452
P407
P50
P577
2013-10-01T00:00:00Z